|Traded as||FWB: MDG|
|Predecessor(s)||Munich Gene Center|
|Key people||Frank Mathias (CEO), Ernst-Ludwig Winnacker (Chairman of the supervisory board)|
|Products||Pharmaceuticals for treatment of cancer and autoimmune diseases|
|Revenue||€37.9 million (2009)|
|Operating income||(€19.6 million) (2009)|
|Profit||(€22.0 million) (2009)|
|Employees||110 (end 2009)|
MediGene AG is a German biotechnology company established in 1994. It is involved in the development of drugs to treat pancreatic cancer. The company has two marketed products: Eligard (leuprorelin) for prostate cancer and Veregen (sinecatechins) for genital warts. It has three other products in clinical development for the treatment of hormone-resistant breast cancer, pancreatic cancer, and rheumatoid arthritis.
- "Annual Report 2009". MediGene. Retrieved 22 August 2010.
- "MediGene drug extends pancreatic cancer survival". Reuters. 2008-09-18.
|This German corporation or company article is a stub. You can help Wikipedia by expanding it.|